Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.2260
-0.0324-12.54%
Post-market: 0.22900.0030+1.33%16:35 EDT
Volume:123.59M
Turnover:36.81M
Market Cap:6.88M
PE:-0.06
High:0.3713
Open:0.3709
Low:0.2015
Close:0.2584
52wk High:2.98
52wk Low:0.1901
Shares:30.44M
Float Shares:28.51M
Volume Ratio:271.20
T/O Rate:433.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:0.89
PE(LYR):-0.01

Loading ...

Keras Resources Delays Annual Results as Strategic Deal Talks Prompt AIM Share Suspension

TIPRANKS
·
Jun 30

Oberon AIM VCT Wins Strong Shareholder Backing at 2026 AGM

TIPRANKS
·
Jun 30

Bravura Solutions Targets AIM Dual Listing to Boost Global Investor Reach

TIPRANKS
·
Jun 30

Silver Bullet shifts year end as AIM trading faces suspension

TIPRANKS
·
Jun 30

Cirata seeks shareholder approval for £5.4m AIM fundraising and share issue

TIPRANKS
·
Jun 30

Restore plc cancels 151,500 shares after AIM buyback

TIPRANKS
·
Jun 29

Caspian Sunrise Faces AIM Trading Suspension Over Delayed 2025 Results

TIPRANKS
·
Jun 26

RTX’s Raytheon awarded $1.1B contract to produce AIM-9X Block II missiles

TIPRANKS
·
Jun 26

Octopus AIM VCT Chair to Take Board Role at Herald Investment Trust

TIPRANKS
·
Jun 26

80 Mile wins AIM Company of the Year as it advances Greenland energy and Italian biofuels portfolio

TIPRANKS
·
Jun 26

Silver Bullet Data Services Wins Shareholder Backing to Delist from AIM and Go Private

TIPRANKS
·
Jun 25

EPE Special Opportunities Increases Treasury Stock with AIM Share Buyback

TIPRANKS
·
Jun 25

CPP Group to Delist from AIM and Raise £5m to Support Blink Parametric

TIPRANKS
·
Jun 25

Hargreave Hale AIM VCT Cuts Share Count with Targeted Buyback

TIPRANKS
·
Jun 25

Maven Renovar VCT wins full AGM backing for AIM Plus strategy shift

TIPRANKS
·
Jun 24

Gana Media Director Increases Stake with AIM Share Purchase

TIPRANKS
·
Jun 24

AIM Immunotech Completes Phase 2 Duripanc Trial Enrollment for Ampligen-imfinzi in Metastatic Pancreatic Cancer

Reuters
·
Jun 24

AIM Immunotech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

THOMSON REUTERS
·
Jun 24

AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones

GlobeNewswire
·
Jun 24

Blow to AIM as pawnbroker Ramsdens snapped up by US giant for £206m

cityam
·
Jun 23